Intracranial hemorrhage in patients with cancer treated with bevacizumab: The memorial Sloan-Kettering experience

Annals of Oncology

Volumn 23, Issue 2, 2012, Pages 458-463

  Khasraw, M ^a   Holodny, A ^a   Goldlust, S A ^a   Deangelis, L M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Intracranial hemorrhage; Metastatic brain tumors; Primary brain tumors; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; LOW MOLECULAR WEIGHT HEPARIN;

AGED; ANGIOSARCOMA; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN TUMOR; CANCER PATIENT; COLON CANCER; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GLIOBLASTOMA; HUMAN; INCIDENCE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

EID: 84856316275     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr148     Document Type: Article

References (17)

1. Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010; 12: 26-33.
2. Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
3. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol 2008; 53: 376-381.
4. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 2008; 10: 624-630.
5. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16(1): 269-278.
6. Vredenburgh JJ, Desjardins A, Herndon JE II et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729.
7. Navi BB, Reichman JS, Berlin D et al. Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology 2010; 74: 494-501.
8. Rogers LR. Cerebrovascular complications in patients with cancer. Semin Neurol 2004; 24: 453-460.
9. Socinski MA, Langer CJ, Huang JE et al. Safety of bevacizumab in patients with nonsmall-cell lung cancer and brain metastases. J Clin Oncol 2009; 27: 5255-5261.
10. Lu JF, Bruno R, Eppler S et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008; 62: 779-786.
11. Verheul HM, Lolkema MP, Qian DZ et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res 2007; 13: 5341-5347.
12. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-624.
13. Saif MW, Mehra R. Incidence and management of bevacizumab-related toxicities in colorectal cancer. Expert Opin Drug Saf 2006; 5: 553-566.
14. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
15. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
16. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.
17. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.